– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation...
Assembly Biosciences: Q4 Earnings Snapshot
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –
– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179,...
Assembly Biosciences: Q3 Earnings Snapshot
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital...
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif.,...
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,...
– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions...